EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors

Hoang, Thang Manh; Mandleywala, Komal; Viray, Tara; Tan, Kel Vin; Lewis, Jason S.; Pereira, Patrícia M. R.

doi:10.1007/s11307-022-01708-2

Cited by 7 publications

(6 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean BCa tumor detection time in a syngeneic orthotopic model using MUI was found to be 10 days, ranging from 8 to 17 days, whereas that for the clinical symptoms of BCa was 20.8 days, ranging from 14 to 28 days [ 21 , 40 , 43 ]. Subsequent studies were able to detect orthotopic BCa tumors as early as 4 [ 39 ], 7 [ 47 ] and 11 days [ 38 , 40 , 48 ], which did not appear to be influenced by the cell line or mouse strain. Conversely, a more recent study was unable to detect tumors in a syngeneic orthotopic model until the thirteenth day and mice began to die on the sixteenth day from clinical symptoms [ 44 ].…”

Section: Non-invasive Imaging Modalitiesmentioning

confidence: 99%

“…Immuno-PET is another branch of PET imaging that utilizes antibodies for the specific targeting of molecules expressed by cancer cells and tumors. In an orthotopic xenograft model, detection of the epidermal growth factor receptor (EGFR)-expressing BCa cells by the radioimmunoconjugate [ 89 Zr] Zr-DFO-panitumumab was investigated [ 48 ] ( Figure 3 ). Imaging after 72 h after intravenous administration, [ 89 Zr] Zr-DFO-panitumumab injection resulted in tumor size-dependent accumulation, with a correlation coefficient of 0.99 exhibiting the quantitative capability of PET.…”

Section: Non-invasive Imaging Modalitiesmentioning

confidence: 99%

“…Imaging after 72 h after intravenous administration, [ 89 Zr] Zr-DFO-panitumumab injection resulted in tumor size-dependent accumulation, with a correlation coefficient of 0.99 exhibiting the quantitative capability of PET. Interestingly, these mice demonstrated inconsistencies in their EGFR protein expression and tumor sizes [ 48 ]. Thus, it is speculated that the strong correlation is caused by the non-specific binding of the antibody due to enhanced permeability and retention effects.…”

Section: Non-invasive Imaging Modalitiesmentioning

confidence: 99%

See 2 more Smart Citations

Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer

Relouw

Dugbartey

Şener

2023

Cancers

View full text Add to dashboard Cite

Bladder cancer (BCa) is the sixth most prevalent cancer in men and seventeenth most prevalent cancer in women worldwide. Current treatment paradigms have limited therapeutic impact, suggesting an urgent need for the investigation of novel therapies. To best emulate the progression of human BCa, a pre-clinical intravesical murine model is required in conjunction with existing non-invasive imaging modalities to detect and evaluate cancer progression. Non-invasive imaging modalities reduce the number of required experimental models while allowing for longitudinal studies of novel therapies to investigate long-term efficacy. In this review, we discuss the individual and multi-modal use of non-invasive imaging modalities; bioluminescence imaging (BLI), micro-ultrasound imaging (MUI), magnetic resonance imaging (MRI), and positron emission tomography (PET) in BCa evaluation. We also provide an update on the potential and the future directions of imaging modalities in relation to intravesical murine models of BCa.

show abstract

Section: Non-invasive Imaging Modalitiesmentioning

confidence: 99%

Section: Non-invasive Imaging Modalitiesmentioning

confidence: 99%

Section: Non-invasive Imaging Modalitiesmentioning

confidence: 99%

See 1 more Smart Citation

Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer

Relouw

Dugbartey

Şener

2023

Cancers

View full text Add to dashboard Cite

show abstract

“…Finally, Hoang et al investigated the ability of the radioimmunoconjugate [ 89 Zr]Zr-DFO-Panitumumab to detect epidermal growth factor receptor (EGFR) expression in an orthotopic mouse model of BC, with encouraging results. Indeed, EGFR is often overexpressed in BC [69]. Human epidermal growth factor 2 (HER2) is less commonly overexpressed in BC (about 13% of cases), but could be imaged using the radiolabelled agent [ 89 Zr]Zr-trastuzumab [70].…”

Section: Ici Tracers and Targeted Therapiesmentioning

confidence: 99%

PET Imaging in Bladder Cancer: An Update and Future Direction

et al. 2023

View full text Add to dashboard Cite

Molecular imaging with positron emission tomography is a powerful tool in bladder cancer management. In this review, we aim to address the current place of the PET imaging in bladder cancer care and offer perspectives on potential future radiopharmaceutical and technological advancements. A special focus is given to the following: the role of [18F] 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in the clinical management of bladder cancer patients, especially for staging and follow-up; treatment guided by [18F]FDG PET/CT; the role of [18F]FDG PET/MRI, the other PET radiopharmaceuticals beyond [18F]FDG, such as [68Ga]- or [18F]-labeled fibroblast activation protein inhibitor; and the application of artificial intelligence.

show abstract

“…ImmunoPET studies on other malignancies are still in the preclinical setting. For instance, early murine studies targeting EGFR and CA 19-9 were promising in bladder cancer models ( 404 , 405 ). An anti-CD3 probe also detected T-cell infiltration in bladder cancer-bearing mice, reflecting the potential for future studies on immunotherapy response prediction in urothelial cancers ( 406 ).…”

Section: Immunopet In Different Malignanciesmentioning

confidence: 99%

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

et al. 2022

View full text Add to dashboard Cite

Immuno-positron emission tomography (immunoPET) is a molecular imaging modality combining the high sensitivity of PET with the specific targeting ability of monoclonal antibodies. Various radioimmunotracers have been successfully developed to target a broad spectrum of molecules expressed by malignant cells or tumor microenvironments. Only a few are translated into clinical studies and barely into clinical practices. Some drawbacks include slow radioimmunotracer kinetics, high physiologic uptake in lymphoid organs, and heterogeneous activity in tumoral lesions. Measures are taken to overcome the disadvantages, and new tracers are being developed. In this review, we aim to mention the fundamental components of immunoPET imaging, explore the groundbreaking success achieved using this new technique, and review different radioimmunotracers employed in various solid tumors to elaborate on this relatively new imaging modality.

show abstract

EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors

Cited by 7 publications

References 48 publications

Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer

Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer

PET Imaging in Bladder Cancer: An Update and Future Direction

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

Contact Info

Product

Resources

About